Progenics Pharma (PGNX) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2015 Financial and Business Results
March 11, 2016 8:00 AM ESTRELISTOR® Net Sales Increased to $23.0 Million for the Fourth Quarter Oral RELISTOR Remains On-track for April 19, 2016 PDUFASubcutaneous RELISTOR Approved in Europe for All Opioid-Induced ConstipationAZEDRA® Ultra-Orphan Cancer Therapeutic Receives FDA Breakthrough DesignationAZEDRA Completes Enrollment of 68 Patients in Pivotal Trial and Topline Results Expected Between December 2016 and March 2017Initiated Pivotal Phase 3 Study of 1404, PSMA-Targeted SPECT/CT Imaging Agent Clinical Studies Planned for PyL PSMA-Targeted PET/CT Imaging Agent Licensed... More
